March 13th 2023
The final analysis of the phase 2/3 CCTG IND.227/KEYNOTE-483 trial identifies a statistically significant survival benefit with pembrolizumab and chemotherapy vs chemotherapy alone in the first-line setting for patients with unresectable advanced or metastatic malignant pleural mesothelioma.
Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Trekking Through the Latest Updates for ROS1-Targeted Therapies
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
Mapping Out the Role of Emerging Biomarkers and Testing in NSCLC
Navigating the Latest Data on NTRK-Targeted Therapies
Community Practice Connections™: 17th Annual New York Lung Cancers Symposium
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
Show Me Your Care Plan™: Monitoring and Managing Patients With EGFR Exon20 Insertion+ NSCLC
Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care
Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers
Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care
Advancing Precision Care Through Biomarker-Driven Therapy: CEACAM5 as a Therapeutic Target in NSCLC
Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer
Medical Crossfire: How Should We Leverage Multidisciplinary Lung Cancer Care Teams in Managing Earlier Forms of NSCLC... When the Goal Is Cure?
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
Catching Them Early: A Real-World Case Discussion on the Application of Testing Methodologies to Identify Key Markers Across NSCLC
Expert Illustrations & Commentaries™: Exploring the Clinical Rationale for Antagonizing Inflammatory IL-1-beta Signaling in NSCLC
Onco-Nurse Academy™: Exploring an Advent of Targeted Therapies Across Advanced NSCLC Care and Strategies for Managing Adverse Events Associated With Treatment
Patient, Provider, and Caregiver Connection™: Shedding a Light on the Patient Journey with KRAS Mutated Lung Cancer
Clinical Vignettes®: Multidisciplinary Discussions on the Application of Novel EGFR Exon 20 Targeted Regimens for NSCLC Management
Expert Illustrations & Commentaries™: Exploring the Role of Novel Antibody-Drug Conjugates in Advanced NSCLC
Advances In™ NSCLC: Exploring CEACAM5 As A New Therapeutic Target
Community Practice Connections™: Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!
Community Practice Connections™: Analyzing the Evolving Role of Liquid Biopsies Across Cancer Care
Advances In™: The Role of NRG1 Fusions Across Tumor Types
Medical Crossfire®: Leveraging EGFR Mutation Profiles to Personalize Therapeutic Decisions in Resected and Metastatic NSCLC Settings
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!
Proton Radiotherapy in Patients with LA-NSCLC May Aid in Reducing Risk of Heart DiseaseNovember 14th 2020
This study found that found that mini-strokes and heart attacks were significantly less common among patients with locally advanced non-small cell lung cancer who underwent proton therapy versus conventional photon-based radiation therapy.
Merck Stops Phase 3 KEYNOTE-598 Trial in Metastatic NSCLCNovember 10th 2020
Merck is discontinuing the study after an independent Data Monitoring Committee recommendation, which determined the benefit/risk profile of pembrolizumab in combination with ipilimumab did not support continuing the trial.
Study Strengthens Case for SBRT Use in Oligometastatic Neoplasia to the LungNovember 3rd 2020
This study indicated that patients with up to 3 lung metastases from primary tumors in other sites who were treated with stereotactic body radiation therapy fared comparably well whether their radiation was delivered in 1 or 4 treatment sessions.
Fragment Analysis Able to Detect MET exon 14 Skipping Deletions in NSCLC Missed by NGSNovember 2nd 2020
This study found that fragment analysis had the ability to detect large MET exon 14 skipping deletions that were missed by next-generation sequencing in non-small cell lung cancer tumor samples.
FDA Grants Priority Review to Cemiplimab-rwlc as First-Line Treatment for Advanced NSCLCOctober 29th 2020
The FDA granted priority review to the supplemental biologics license application for cemiplimab-rwlc (Libtayo) as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer with 50% or more PD-L1 expression.
FDA Grants Priority Review to Osimertinib for Adjuvant Treatment of Early-Stage EGFRm NSCLCOctober 20th 2020
The FDA accepted and granted priority review to the supplemental new drug application for osimertinib (Tagrisso) for the adjuvant treatment of patients with early-stage EGFR-mutated non-small cell lung cancer after complete tumor resection with curative intent.
Two Studies Examining Pembrolizumab Combinations Induce Positive Outcomes in Advanced NSCLCOctober 19th 2020
Merck announced positive data regarding 2 studies, one examining pembrolizumab in combination with chemotherapy and another in combination with quavonlimab in combination to treat advanced non-small cell lung cancer.
Phase 3 CheckMate-816 Trial Meets Primary End Point in Resectable NSCLCOctober 7th 2020
Significantly more patients treated with nivolumab (Opdivo) plus chemotherapy before surgery demonstrated no evidence of cancer cells in their resected tissue in the trial compared to those treated with chemotherapy alone.
Study Supports Pembrolizumab Plus Chemo as Standard of Care for PD-L1-Negative Advanced NSCLCOctober 4th 2020
A pooled analysis of 3 randomized controlled trials found that pembrolizumab plus chemotherapy demonstrated response and survival improvements with a manageable safety in comparison with chemotherapy alone in PD-L1‒negative advanced non-small cell lung cancer.
Atezolizumab Appears Effective for Patients with NSCLC with High PD-L1 ExpressionOctober 1st 2020
The findings from this global, open-label, randomized trial supported the FDA approval of atezolizumab for patients with non-small cell lung cancer with high PD-L1 expression, regardless of histologic type, in May.
PORT Not Recommended as Standard of Care for Completely Resected Stage IIIAN2 NSCLCSeptember 26th 2020
Post-operative radiotherapy was associated with a nonstatistically significant increase in disease-free survival in patients with completely resected stage IIIAN2 non-small cell lung cancer and therefore cannot be recommended as a standard of care.
Phase 3 EMPOWER-Lung 1 Shows Promise for Cemiplimab-rwlc in Advanced PD-L1+ NSCLCSeptember 23rd 2020
Cemiplimab-rwlc (Libtayo) monotherapy led to a significant improvement in overall survival and progression-free survival in patients with advanced non-small cell lung cancer with PD-L1 expression on at least 50% of their tumor cells.
Capmatinib Shows Antitumor Activity in Advanced NSCLC with a MET exon 14 Skipping MutationSeptember 10th 2020
Capmatinib (Tabrecta) demonstrated substantial antitumor activity in patients with advanced non-small cell lung cancer with a MET exon 14 skipping mutation, especially in those not treated previously.
FDA Approves Pralsetinib for Treatment of Adults with Metastatic RET Fusion-Positive NSCLCSeptember 8th 2020
The approval was based on results from the phase 1/2 ARROW clinical trial, which demonstrated efficacy for pralsetinib in patients with RET fusion-positive NSCLC with or without prior therapy, and regardless of RET fusion partner or central nervous system involvement.
FDA Grants Priority Review to Tepotinib for the Treatment of NSCLC with METex14 Skipping MutationsAugust 26th 2020
The new drug application was based on results from the pivotal ongoing, single-arm, phase 2 VISION study evaluating tepotinib monotherapy in patients with advanced NSCLC with METex14 skipping alterations.
FDA Approves Generic Form of Pemetrexed for Non-Squamous NSCLCAugust 25th 2020
The FDA approved a generic form of pemetrexed for injection as a single-agent in patients with locally advanced or metastatic non-squamous non-small cell lung cancer that has not progressed after 4 cycles of first-line platinum-based chemotherapy.
TRIDENT-1 Trial for Repotrectinib Shows Encouraging Data in Subgroup of Patients with NSCLCAugust 20th 2020
Early interim data from the registrational phase 2 TRIDENT-1 study of repotrectinib was reported by Turning Point Therapeutics, as well as regulatory feedback from the FDA regarding the TRIDENT-1 trial design.
PLCOm2012 Model May Be More Effective in Screening African Americans for Lung CancerAugust 19th 2020
These findings suggest that the current lung cancer screening guidelines undercount African Americans and should therefore be modified to avoid worsening the observed disparities between white and African American ever-smokers in lung cancer outcomes.
FDA Grants Priority Review for Less Frequent, Fixed Dose of DurvalumabAugust 18th 2020
If approved, durvalumab could be administered intravenously every 4 weeks at a fixed dose of 1500 mg in unresectable stage III NSCLC after chemoradiation therapy and in previously treated advanced bladder cancer.